- Home
- TCBS vs MAIA Comparison
TCBS vs MAIA Comparison
Compare TCBS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TCBS | MAIA |
|---|---|---|
| Founded | 1934 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.3M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | TCBS | MAIA |
|---|---|---|
| Price | $16.00 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 224.1K |
| Earning Date | 11-07-2025 | 11-07-2025 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $15,268,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.44 | ★ N/A |
| Revenue Growth | ★ 54.88 | N/A |
| 52 Week Low | $14.85 | $0.87 |
| 52 Week High | $19.40 | $2.74 |
Technical Indicators
Market Signals| Indicator | TCBS | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 49.13 |
| Support Level | $15.90 | $0.87 |
| Resistance Level | $15.95 | $1.09 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 96.15 | 86.21 |
Price Performance
Historical ComparisonAbout TCBS Texas Community Bancshares Inc.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.